6.
Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L
. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 2017; 184:7-14.
PMC: 5362328.
DOI: 10.1016/j.imlet.2017.02.006.
View
7.
Cerezo M, Guemiri R, Druillennec S, Girault I, Malka-Mahieu H, Shen S
. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat Med. 2018; 24(12):1877-1886.
DOI: 10.1038/s41591-018-0217-1.
View
8.
Ribas A, Hu-Lieskovan S
. What does PD-L1 positive or negative mean?. J Exp Med. 2016; 213(13):2835-2840.
PMC: 5154949.
DOI: 10.1084/jem.20161462.
View
9.
Durand S, Tang Y, Pommier R, Benboubker V, Grimont M, Boivin F
. ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions. Oncogene. 2024; 43(20):1489-1505.
PMC: 11090790.
DOI: 10.1038/s41388-024-03010-7.
View
10.
Guo Y, Lu X, Chen Y, Rendon B, Mitchell R, Cuatrecasas M
. Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells. Sci Adv. 2021; 7(21).
PMC: 8139582.
DOI: 10.1126/sciadv.abd7455.
View
11.
Benboubker V, Boivin F, Dalle S, Caramel J
. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma. Front Immunol. 2022; 13:873116.
PMC: 9012258.
DOI: 10.3389/fimmu.2022.873116.
View
12.
Taube J, Klein A, Brahmer J, Xu H, Pan X, Kim J
. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20(19):5064-74.
PMC: 4185001.
DOI: 10.1158/1078-0432.CCR-13-3271.
View
13.
Boshuizen J, Vredevoogd D, Krijgsman O, Ligtenberg M, Blankenstein S, de Bruijn B
. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nat Commun. 2020; 11(1):3946.
PMC: 7414147.
DOI: 10.1038/s41467-020-17739-8.
View
14.
Shrestha R, Bridle K, Crawford D, Jayachandran A
. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Mol Med Rep. 2020; 21(4):1849-1860.
PMC: 7057769.
DOI: 10.3892/mmr.2020.10991.
View
15.
Hugo W, Zaretsky J, Sun L, Song C, Moreno B, Hu-Lieskovan S
. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016; 165(1):35-44.
PMC: 4808437.
DOI: 10.1016/j.cell.2016.02.065.
View
16.
Mezzadra R, Sun C, Jae L, Gomez-Eerland R, de Vries E, Wu W
. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017; 549(7670):106-110.
PMC: 6333292.
DOI: 10.1038/nature23669.
View
17.
Nirmal A, Maliga Z, Vallius T, Quattrochi B, Chen A, Jacobson C
. The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. Cancer Discov. 2022; 12(6):1518-1541.
PMC: 9167783.
DOI: 10.1158/2159-8290.CD-21-1357.
View
18.
Casey S, Tong L, Li Y, Do R, Walz S, Fitzgerald K
. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016; 352(6282):227-31.
PMC: 4940030.
DOI: 10.1126/science.aac9935.
View
19.
Marine J, Dawson S, Dawson M
. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020; 20(12):743-756.
DOI: 10.1038/s41568-020-00302-4.
View
20.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C
. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546.
DOI: 10.1056/NEJMoa1910836.
View